


CABATEN GETNE T1914

Pls: Dr. Jaume Capdevila | Dr. Enrique Grande

Exploratory basket trial of CABozantinib plus ATezolizumab in advanced and progressive neoplasms of the ENdocrine system (CABATEN study)

NEXT OPENING



Primary endpoint:

Overall Objective Response Rate (ORR)

Estimated Primary Completion Date: 3Q
2021 (S1), 2023 (S2)